Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion type Assertion NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_head.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion description "[Although anti-CD19 CAR T cells are at an early stage of development, the potent antigen-specific activity observed in patients suggests that infusions of anti-CD19 CAR T cells might become a standard therapy for some B-cell malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion evidence source_evidence_literature NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion SIO_000772 23546520 NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion wasDerivedFrom befree-20150227 NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion wasGeneratedBy ECO_0000203 NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.